Current status of screening for colorectal cancer

Ann Oncol. 2013 Aug;24(8):1963-72. doi: 10.1093/annonc/mdt157. Epub 2013 Apr 25.

Abstract

Background: Colorectal cancer (CRC) is a leading cause of cancer morbidity and mortality. A well-defined precursor lesion (adenoma) and a long preclinical course make CRC a candidate for screening. This paper reviews the current evidence for the most important tests that are widely used or under development for population-based screening.

Material and methods: In this narrative review, we scrutinized all papers we have been aware of, and carried out searches in PubMed and Cochrane library for relevant literature.

Results: Two screening methods have been shown to reduce CRC mortality in randomised trials: repetitive faecal occult blood testing (FOBT) reduces CRC mortality by 16%; once-only flexible sigmoidoscopy (FS) by 28%. FS screening also reduces CRC incidence (by 18%), FOBT does not. Colonoscopy screening has a potentially larger effect on CRC incidence and mortality, but randomised trials are lacking. New screening methods are on the horizon but need to be tested in large clinical trials before implementation in population screening.

Conclusions: FS screening reduces CRC incidence and CRC mortality by removal of adenomas; FOBT reduces CRC mortality by early detection of cancer. Several other tests are available, but none has been evaluated in randomised trials. Screening strategies differ considerably across countries.

Keywords: adenoma; colonoscopy; colorectal cancer; prevention; screening.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adenoma / diagnosis
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / genetics
  • Colonoscopy
  • Colorectal Neoplasms / diagnosis*
  • Colorectal Neoplasms / mortality
  • Colorectal Neoplasms / prevention & control*
  • Early Detection of Cancer*
  • Humans
  • Mass Screening / methods*
  • Occult Blood
  • Patient Compliance
  • Sensitivity and Specificity
  • Sigmoidoscopy

Substances

  • Biomarkers, Tumor